--- a
+++ b/clusters/9knumclustersv2/clust_1404.txt
@@ -0,0 +1,14 @@
+Received > mg/m equivalents of daunorubicin (see Appendix G for conversion table)
+Received > mg/m equivalents of daunorubicin
+Eligible for intensive cytarabine/daunorubicin (+) chemotherapy specified
+Patients who have received >  mg/m^ daunorubicin equivalents; patients who relapse after receiving AAML/AAML therapy will be eligible for this study, provided they have not received any additional anthracyclines; NOTE: for the purposes of determining eligibility for this protocol, the following cardiotoxicity multipliers will be used to determine daunorubicin equivalents:\r\n* Doxorubicin (doxorubicin hydrochloride): \r\n* Mitoxantrone: \r\n* Idarubicin: \r\n* Epirubicin: .
+Patients with prior allergy to daunorubicin and/or cytarabine
+Predicted inability to tolerate standard induction chemotherapy with daunorubicin and cytarabine
+Hypersensitivity to cytarabine, daunorubicin or liposomal products
+Patients who have previously had >  mg/m^ cumulative dose of daunorubicin or >  mg/m^ daunorubicin-equivalent anthracycline therapy (for example, from prior treatment of solid tumors)
+Known hypersensitivity to cytarabine, daunorubicin or liposomal products
+Hypersensitivity to cytarabine, daunorubicin or liposomal products
+Hypersensitivity to cytarabine, daunorubicin or liposomal products
+Eligible for induction by daunorubicin + cytarabine.
+Hypersensitivity to cytarabine, daunorubicin or liposomal products
+Relapsed patients:\r\n* Second or greater relapse OR\r\n* AML in first relapse AND has received >=  mg/m^ daunorubicin equivalents \r\n* NOTE: for the purposes of determining eligibility for this protocol, the following cardiotoxicity multipliers will be used to determine daunorubicin equivalents:\r\n** Doxorubicin: \r\n** Mitoxantrone: \r\n** Idarubicin: \r\n** Epirubicin: .